3min chapter

Value Hive Podcast cover image

Q3 2022 Investor Audibles: Third Point Capital, Ensemble Capital, Greenlight Capital

Value Hive Podcast

CHAPTER

Third-Path Investing in Ventix

Ventix is a biotechnology company focused on treating autoimmune diseases by discovering and developing next-generation small molecule drugs for well-validated targets. Third-point first invested in Ventix in 2016 as an investment in Opelian, which was developing in an oral small molecule for ulcerative colitis with a post-money valuation of roughly $20 million. In early 2021, third-point along with management agreed to merge our opelian investment into Ventix to consolidate all autoimmune disorder assets run by the same management team under one company. We found the consolidated R&D pipeline, especially Ventix's TYK2 inhibitor commercially very attractive. The merger allowed the company to bulk

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode